Inproteo, a joint venture among Eli Lilly and Co. and Purdue and Indiana Universities, has named Peter Kissinger as President and Chief Executive Officer.

Indianapolis, September 1, 2005 -- Inproteo, an industry/university consortium formed to develop and commercialize proteomics tools, has appointed board member and entrepreneur Peter Kissinger as its President and Chief Executive Officer.

Inproteo, the commercial name for the Indiana Proteomics Consortium, LLC, was established in 2002 as a joint effort by Eli Lilly and Co. and Purdue and Indiana Universities. The group has since organized two start-up companies to commercialize technologies developed through the consortium’s efforts, Tienta Sciences Inc. who develops and manufactures products for the biotechnology and pharmaceutical industries, and Prosolia Inc. who commercializes mass spectrometry technology.

Kissinger, who is and will continue as, chairman and CEO of BASi (Bioanalytical Systems, Inc.), succeeds John Hurrell, who has decided to pursue other opportunities in the life sciences.

“Pete Kissinger’s extensive business experience and scientific knowledge will keep Inproteo moving forward while we plot a course for its future leadership and success,” said Sally Mason, chairman of the Inproteo board and Purdue’s provost.

“The consortium will be in good hands, and we are off to an excellent start, thanks to John Hurrell’s work. We will miss John’s leadership, but he feels this is the right time for both him and Inproteo to make a change, and I respect his decision. John built an excellent foundation for us in proteomics, and he also has helped Inproteo launch promising spin-off companies such as Tienta and Prosolia.”

Regarding Inproteo’s future prospects, Hurrell said, “I am very proud of what Inproteo has achieved, thanks to the work of many talented people and the support of our board. It was an inspired decision to combine Purdue’s and IU’s world-class research in proteomic tools and analytical methods with Eli Lilly’s strength in protein therapeutics. I believe Inproteo is positioned to help Indiana develop a very important segment of the life sciences sector.”

As President and CEO, Kissinger will direct an assessment of the great progress Inproteo has made to date and direct planning for the future. He remains CEO of BASi (Bioanalytical Systems), the company he founded, a pharmaceutical development company providing contract research services and monitoring instruments to leading drug development companies worldwide.

“Inproteo has made great strides under John Hurrell and has the potential to become a tremendous asset for Indiana,” Kissinger said. “I am excited about the challenge of leading its efforts and I look forward to working with the many talented people involved in its work.”

Kissinger earned his doctorate at the University of North Carolina. He served on the faculty at Michigan State University from 1972-75 before joining Purdue, where he works part time as a chemistry professor. He founded BASi in1974.

Hurrell earled his doctorate in protein and peptide chemistry at the University of Melbourne, Australia. He previously was general manager of Tripath Oncology located in Research Triangle Park, N.C.

Bill Chin, vice president of Lilly Research Laboratories at Eli Lilly and Co. and a member of Inproteo’s board of managers said, “An outstanding feature of Inproteo has been to develop new and unique analytical technologies that are clearly ripe for further development. Our goal continues to be to help grow the life sciences sector here in Indiana.”

As was planned, Inproteo has generated funding beyond the initial investment of the founders through licensing or technologies, government grants and other sources.